| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mori T et al. | RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. | 2004 | Nucleic Acids Res. | pmid:15562003 |
| Ling JQ and Li JP | [Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2004 | Hua Xi Kou Qiang Yi Xue Za Zhi | pmid:15562643 |
| Zhang D et al. | [Expression of OPG and RANKL at protein level in human periodontal ligament cells and the effect of 1alpha,25(OH)(2) vitamin D(3) on the secretion of OPG protein in vitro]. | 2004 | Beijing Da Xue Xue Bao | pmid:15605102 |
| Brubaker KD et al. | Bone morphogenetic protein signaling in prostate cancer cell lines. | 2004 | J. Cell. Biochem. | pmid:14689587 |
| Zhang D et al. | The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. | 2004 | Arch. Oral Biol. | pmid:14693199 |
| Sohen S | [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases]. | 2004 | Nippon Rinsho | pmid:15035207 |
| Tanaka Y | [Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases]. | 2004 | Nippon Rinsho | pmid:15035208 |
| Fukunaga J and Sugahara T | [Osteoporosis induced by immunosuppressant]. | 2004 | Nippon Rinsho | pmid:15035219 |
| Juji T and Tanaka S | [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination]. | 2004 | Nippon Rinsho | pmid:15035230 |
| Huang JC et al. | PTH differentially regulates expression of RANKL and OPG. | 2004 | J. Bone Miner. Res. | pmid:14969393 |
| Saidenberg-Kermanac'h N et al. | Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. | 2004 | J. Clin. Immunol. | pmid:15163893 |
| Melhus H | Soluble RANKL and risk of nontraumatic fracture. | 2004 | JAMA | pmid:15187049 |
| Pennisi P et al. | Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | 2004 | Osteoporos Int | pmid:14661073 |
| Saidenberg-Kermanac'h N et al. | TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. | 2004 | Bone | pmid:15542046 |
| Boabaid F et al. | The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. | 2004 | J. Periodontol. | pmid:15515341 |
| Franck H et al. | Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. | 2004 | J. Rheumatol. | pmid:15517638 |
| Ueland T | Bone metabolism in relation to alterations in systemic growth hormone. | 2004 | Growth Horm. IGF Res. | pmid:15519248 |
| Kitaura H et al. | Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. | 2004 | J. Immunol. | pmid:15470024 |
| Price PA et al. | Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. | 2004 | J. Biol. Chem. | pmid:14578360 |
| Tian QX and Huang GY | [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. | 2004 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | pmid:15379268 |
| Nitta K et al. | Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. | 2004 | Am. J. Kidney Dis. | pmid:15384019 |
| Kanatani M et al. | Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. | 2004 | J. Cell. Physiol. | pmid:15281085 |
| Xiao XH et al. | [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15730627 |
| Matsuo K and Ray N | Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. | 2004 | Keio J Med | pmid:15247511 |
| Tiranathanagul S et al. | Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. | 2004 | J. Periodontol. | pmid:15732867 |
| Mosheimer BA et al. | Expression and function of RANK in human monocyte chemotaxis. | 2004 | Arthritis Rheum. | pmid:15248232 |
| Xu D et al. | Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. | 2004 | Biochem. J. | pmid:15250821 |
| De Leenheer E et al. | Evidence of a role for RANKL in the development of myeloma bone disease. | 2004 | Curr Opin Pharmacol | pmid:15251126 |
| Taranta A et al. | Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. | 2004 | J. Bone Miner. Res. | pmid:15176994 |
| Demer LL and Abedin M | Skeleton key to vascular disease. | 2004 | J. Am. Coll. Cardiol. | pmid:15542279 |
| Coetzee M and Kruger MC | Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? | 2004 | South. Med. J. | pmid:15180028 |
| Vidal K et al. | Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. | 2004 | Am. J. Physiol. Gastrointest. Liver Physiol. | pmid:15521102 |
| Abedin M et al. | Vascular calcification: mechanisms and clinical ramifications. | 2004 | Arterioscler. Thromb. Vasc. Biol. | pmid:15155384 |
| Vidal K et al. | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. | 2004 | Pediatr. Res. | pmid:15155868 |
| Xiao HL et al. | Expression and identification of mutated osteoprotegerin in culture cells and larvae of silkworm. | 2004 | Acta Biochim. Biophys. Sin. (Shanghai) | pmid:15156274 |
| Franchimont N et al. | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. | 2004 | Clin. Exp. Immunol. | pmid:15544627 |
| Ichinose Y et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | 2004 | Calcif. Tissue Int. | pmid:15549649 |
| Collin-Osdoby P | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. | 2004 | Circ. Res. | pmid:15564564 |
| Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
| Mizutani Y et al. | Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. | 2004 | Cancer | pmid:15386310 |
| Salmon P | Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. | 2004 | J. Bone Miner. Res. | pmid:15068491 |
| Morabito N et al. | Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. | 2004 | J. Bone Miner. Res. | pmid:15068494 |
| Durán A et al. | The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. | 2004 | Dev. Cell | pmid:14960283 |
| Wang FS et al. | Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. | 2004 | Endocrinology | pmid:14962990 |
| Harashima SI et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. | 2004 | Rheumatology (Oxford) | pmid:14963213 |
| Ambroszkiewicz J et al. | [Biochemical bone resorption markers in children with osteosarcoma]. | 2004 Apr-Jun | Med Wieku Rozwoj | pmid:15738598 |
| Dovio A et al. | [Pathophysiological significance and clinical utility of circulating osteoprotegerin]. | 2004 Jan-Mar | Ann. Ital. Med. Int. | pmid:15176704 |
| Rajzbaum G et al. | French women, fractures and aortic calcifications. | 2005 | J. Intern. Med. | pmid:15606383 |
| Xing L et al. | Osteoclast precursors, RANKL/RANK, and immunology. | 2005 | Immunol. Rev. | pmid:16313338 |
| Tanaka S et al. | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. | 2005 | Immunol. Rev. | pmid:16313339 |
| Horowitz MC et al. | B cells and osteoblast and osteoclast development. | 2005 | Immunol. Rev. | pmid:16313346 |
| Clowes JA et al. | The role of the immune system in the pathophysiology of osteoporosis. | 2005 | Immunol. Rev. | pmid:16313351 |
| Wang Q et al. | [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis]. | 2005 | Zhong Yao Cai | pmid:16479929 |
| Guang-Da X et al. | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Endocrinol. Invest. | pmid:16483173 |
| Yamazaki H and Sasaki T | Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. | 2005 | J Electron Microsc (Tokyo) | pmid:16339792 |
| Wang YD et al. | [Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. | 2005 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:16355616 |
| Gajewska J et al. | [The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. | 2005 | Wiad. Lek. | pmid:16238129 |
| Ruocco MG and Karin M | IKK{beta} as a target for treatment of inflammation induced bone loss. | 2005 | Ann. Rheum. Dis. | pmid:16239395 |
| Xiao HL et al. | [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. | 2005 | Yi Chuan | pmid:16257908 |
| Liu W et al. | Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. | 2005 | J. Biol. Chem. | pmid:16260781 |
| Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
| Burton DW et al. | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. | 2005 | Prostate | pmid:15389781 |
| Zahanich I et al. | Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. | 2005 | J. Bone Miner. Res. | pmid:16059635 |
| Cao JJ et al. | Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. | 2005 | J. Bone Miner. Res. | pmid:16059637 |
| Terpos E et al. | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. | 2005 | Leukemia | pmid:16079895 |
| Olesen P et al. | Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. | 2005 | Diabetologia | pmid:15700136 |
| Pantouli E et al. | Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15721297 |
| Korcok J et al. | P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. | 2005 | J. Biol. Chem. | pmid:15722352 |
| Kiviranta R et al. | Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. | 2005 | Bone | pmid:15664014 |
| Avbersek-Luznik I et al. | Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? | 2005 | Nephrol. Dial. Transplant. | pmid:15665031 |
| Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
| Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
| Skládal P et al. | Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. | 2005 | Biosens Bioelectron | pmid:15741072 |
| Ferrari SL et al. | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. | 2005 | Endocrinology | pmid:15705780 |
| Heymann D et al. | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. | 2005 | Drug Discov. Today | pmid:15708742 |
| Mezquita-Raya P et al. | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. | 2005 | Osteoporos Int | pmid:15711777 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
| Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
| Chang K et al. | Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. | 2005 | J. Orthop. Res. | pmid:15913941 |
| Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
| Mesquita M et al. | Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. | 2005 | Adv Perit Dial | pmid:16686314 |
| Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
| Mazziotti G et al. | Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | 2005 | J. Bone Miner. Res. | pmid:15746993 |
| Corey E et al. | Osteoprotegerin in prostate cancer bone metastasis. | 2005 | Cancer Res. | pmid:15753366 |
| Moschen AR et al. | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. | 2005 | Gut | pmid:15753532 |
| Lau YS et al. | Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. | 2005 | Hum. Pathol. | pmid:16153456 |
| Ueland T and Bollerslev J | Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. | 2005 | Front Horm Res | pmid:16166760 |
| Frick KK et al. | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. | 2005 | Am. J. Physiol. Renal Physiol. | pmid:15972386 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
| Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
| Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
| Koh JM et al. | Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. | 2005 | J. Endocrinol. | pmid:15930166 |
| Liu D et al. | Chronology and regulation of gene expression of RANKL in the rat dental follicle. | 2005 | Eur. J. Oral Sci. | pmid:16202028 |
| Bhattacharya A et al. | Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. | 2005 | J Am Coll Nutr | pmid:15930486 |
| Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |
| Atkins GJ et al. | Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. | 2005 | J. Cell. Physiol. | pmid:15573398 |